Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336717 | 0.83 | CDK4 (0.49) | RAB9ASMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL4908543 | 0.82 | ESR1 (0.41) | RAB9ASMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL1335905 | 0.82 | XDH (0.39) | RAB9ASMN1; SMN2L3MBTL1NPC1ALDH1A1 | |
| SCHEMBL4246815 | 0.82 | PTGS2 (0.47) | RAB9ASMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL1335198 | 0.81 | PTGS2 (0.45) | RAB9ASMN1; SMN2KMT2AMEN1NPC1 | |
| SCHEMBL28220671 | 0.80 | NOTUM (0.41) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL17670183 | 0.80 | KMT2A (0.43) | SMN1; SMN2KMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL16201312 | 0.79 | ALDH1A3 (0.49) | KMT2AMAPK1MAPTNOTUM | |
| SCHEMBL3006649 | 0.78 | NOTUM (0.40) | RAB9ANPC1MAPK1NOTUMKDM4E | |
| SCHEMBL13592411 | 0.78 | NOTUM (0.40) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245132-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC NO 41424 (GB) | 2017-10-18 | — | — | EP | claimed |
| CN-102015993-B | Encapsulated benefit agent | UNILEVER PLC | 2013-03-27 | — | — | CN | claimed |
| CN-102015993-A | Encapsulated benefit agent | UNILEVER PLC | 2011-04-13 | — | — | CN | claimed |
| EP-2245132-A1 | ENCAPSULATED BENEFIT AGENT | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2010-11-03 | — | — | EP | claimed |
| WO-2009103576-A1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC (GB) | 2009-08-27 | — | — | WO | claimed |
| WO-2025125829-A1 | NORA INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| EP-2245132-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC NO 41424 (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-9475831-B2 | Formylpyrrole-based heterocycles for nucleic acid attachment to supports | ILLUMINA, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160137677-A1 | FORMYLPYRROLE-BASED HETEROCYCLES FOR NUCLEIC ACID ATTACHMENT TO SUPPORTS | ILLUMINA, INC. | 2016-05-19 | — | — | US | disclosed |
| US-9273074-B2 | Formylpyrrole-based heterocycles for nucleic acid attachment to supports | ILLUMINA, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2748295-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC (GB) | 2015-10-14 | — | — | EP | disclosed |
| US-20150031833-A1 | FORMYLPYRROLE-BASED HETEROCYCLES FOR NUCLEIC ACID ATTACHMENT TO SUPPORTS | ILLUMINA, INC. | 2015-01-29 | — | — | US | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| CN-102015993-A | Encapsulated benefit agent | UNILEVER PLC | 2011-04-13 | — | — | CN | disclosed |
| EP-2245132-A1 | ENCAPSULATED BENEFIT AGENT | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009103576-A1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC (GB) | 2009-08-27 | — | — | WO | disclosed |
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | SMITHKLINE BEECHMA CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1851204-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SmithKline Beecham Corporation (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006091592-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031833-A1 | FORMYLPYRROLE-BASED HETEROCYCLES FOR NUCLEIC ACID ATTACHMENT TO SUPPORTS | CCNY, FBL, NSUN2 | RAB9A 4620/4885SMN1; SMN2 2481/4885DUSP3 4074/4885 |
| US-20160137677-A1 | FORMYLPYRROLE-BASED HETEROCYCLES FOR NUCLEIC ACID ATTACHMENT TO SUPPORTS | CCNY, FBL, NSUN2 | RAB9A 4620/4885SMN1; SMN2 2481/4885DUSP3 4074/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | RAB9A 2076/4885SMN1; SMN2 1139/4885DUSP3 4702/4885 |
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | NR3C1, NR3C2, NR5A1 | RAB9A 4357/4885SMN1; SMN2 4723/4885DUSP3 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.